Introduction {#Sec1}
============

Management of chronic disease often requires one or more medications to be taken over the full or partial life span of the disease. In this respect, treatment adherence and persistence should be given particular attention as failure to comply may result in earlier deterioration of the condition and sub-optimal outcomes \[[@CR1]\]. In developed countries, adherence to therapies among patients suffering from chronic diseases averages 50%, and it is thought to be even less in developing countries due to reduced access to, and the limitations of, healthcare resources \[[@CR1], [@CR2]\]. With an aging population globally, the burden of people suffering from chronic diseases is expected to increase, resulting in poor health outcomes for individual patients and increases in healthcare costs leading to budgetary challenges for many governments \[[@CR3], [@CR4]\].

Poor adherence is a well-recognised problem among people with type 2 diabetes \[[@CR5]--[@CR8]\], with a high proportion of people failing to take their medication as prescribed \[[@CR9], [@CR10]\]. This can result in worse clinical outcomes, including poor glycaemic control \[[@CR11]--[@CR16]\], increased hospital admissions \[[@CR17]--[@CR20]\], increased healthcare costs \[[@CR21]--[@CR27]\], higher risk of cardiovascular events \[[@CR28], [@CR29]\], increased mortality \[[@CR15], [@CR18], [@CR30]--[@CR32]\], reduced health-related quality of life, and increased burden of diabetes. A meta-analysis by Krass et al. \[[@CR33]\] reported a prevalence of adherence ranging from 38.5% to 93.1%, with the majority of studies (21/27) reporting good adherence in under 80% of people.

Several factors contribute to poor adherence: the World Health Organization (WHO) has identified five main categories \[[@CR1]\]; patient-related (e.g. age), socioeconomic (e.g. medication costs), condition-related (e.g. presence of complications), health-system-related (e.g. level of continuity of care), and therapy-related (e.g. adverse effects) \[[@CR12], [@CR14]\]. There are two discrete patterns of medication non-use, which may be classed as missed medication doses (described by the terms adherence, compliance, or concordance) and duration of use before discontinuation (persistence) \[[@CR34]\]. Accurate assessment of adherence and persistence behaviour, along with accurate data capture and analysis, are necessary for effective and efficient treatment planning, and for ensuring that changes in health outcomes can be attributed to the recommended regimen. Estimated level of persistence (ELPT) (the percentage of individuals remaining on therapy at a given time), the proportion of days covered (PDC) method (the number of days with the drug available divided by the number of days in the specified time interval), or the medication possession ratio (MPR) method (total days supply for all prescriptions filled within a period divided by the number of days in the specified time interval) are often used along with the number of days to discontinuation and number of prescription refills over a period of time \[[@CR35], [@CR36]\].

The aim of the study reported in the present paper was to compare persistence with various oral medications in type 2 diabetic patients, and to identify factors that influence persistence in a real-world setting using a primary-care-based population and with non-persistence defined as a prescription gap of ≥ 90 days.

Methods {#Sec2}
=======

We performed a retrospective cohort analysis in adults with type 2 diabetes to compare medication persistence across all noninsulin medication classes used in the treatment of hyperglycaemia. The cohort was identified from the Royal College of General Practitioners Research and Surveillance Centre (RCGP-RSC) database. This comprises primary care data from a sentinel network of general practices distributed across England. At the time of analysis, the database contained primary care records collected from 1,238,909 people registered with 128 practices. The database includes all recorded clinical codes with associated values and dates for the population from January 1, 2004 to January 1, 2015. These clinical codes are recorded using the Read coding system and include diagnosis codes, medication codes, investigation codes, and process of care codes. This large primary care database has been demonstrated to be representative of the UK population, although less socioeconomically deprived people are slightly overrepresented \[[@CR37]\].

We used a two-step process to identify people with type 2 diabetes, which we have reported in full previously \[[@CR38]\]. In brief, the first step identified all people with diabetes (of any type), defined as those who had a diagnostic code (diagnosis of diabetes), clinical investigations (two or more fasted, random, or glucose tolerance test values or HbA1c measurements consistent with diagnosis), or medication use (two or more prescriptions for oral diabetes medications, excluding metformin or injectable therapies). These people were then categorised by diabetes type using a clinically-based seven-step algorithm. This method was chosen to minimise the impact of misdiagnosis, misclassification and miscoding, which has previously been identified in people with diabetes \[[@CR39], [@CR40]\]. All adults (age ≥ 18 years) with identified type 2 diabetes were included for analysis.

Within the adult type 2 diabetes population, we identified all new medication prescriptions for metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sodium-glucose cotransporter 2 (SGLT2) inhibitors, meglitinides, and alpha-glucosidase inhibitors between January 1, 2005 and December 31, 2015. We did not examine persistence with fixed-dose combination therapies. To be included as a new prescription, we required a minimum of 6 months of registration prior to the first prescription occurrence for the medication of interest. People with only one prescription for the medication of interest were excluded from the analysis. We followed persistence for each newly prescribed medication. Non-persistence was defined as a gap in prescriptions of ≥ 90 days. The duration of persistence was defined as the time interval between the first prescription and the last identified prescription consistent with persistence. Only people currently registered with the primary care practice from which their data were extracted were included. People who had died or were unregistered at the time of data collection (January 1, 2016) were not included. People who had a final prescription for the medication within 90 days of the end of follow-up were categorised as having censored persistence and included for analysis. All available data were used to follow-up people with type 2 diabetes either from registration with their current primary care practice, the earliest available records (January 2004), or the diagnosis of type 2 diabetes (whichever was latest).

People were considered to be non-persistent if they switched medication within a class; for example, a change from sitagliptin to linagliptin was considered to be non-persistence with sitagliptin---two persistence events were then included for analysis (one with sitagliptin and one with linagliptin). People who switched medication preparation (for example metformin standard release to metformin modified release) were considered to be persistent. We only consider primary persistence (i.e. persistence from the first recorded prescription of each medication).

Statistical Methods {#Sec3}
-------------------

For each medication class included, we report the proportion of people remaining persistent at 6 months, 1 year, 2 years, and 5 years, with 95% confidence intervals (95% CI). We also report the crude median persistence duration with each class with 95% confidence intervals.

We used Cox regression analysis to identify the independent influences of multiple variables on medication persistence. Factors included in the regression analysis comprised age, gender, ethnicity, socioeconomic status (measured using the Index of Multiple Deprivation; IMD score), smoking status, alcohol intake, duration of diabetes, glycaemic control, presence of complications, presence of comorbidities, number of concurrent diabetes medications, number of previous non-persistent diabetes medications, and medication class. Ethnicity was defined using the Office of National Statistics (ONS) official UK ethnicity categories: this defines five major ethnic categories: white, mixed/multiple ethnic groups, Asian (including Indian, Pakistani, Bangladeshi, and Chinese people), black (including African and Caribbean people), and other (including Arab and other minority groups not classified elsewhere) \[[@CR41]\].

Socioeconomic status was derived using the nationally recognised measure IMD, based on patient postcode. Smoking status and alcohol use were defined using the most recently recorded measure. Duration of diabetes was defined as the time between the first recorded indicator of diabetes (diagnostic code, blood glucose measure consistent with diabetes, or medication) in the record and the time of initiation of the medication of interest. In the population characteristics table, the duration of diabetes is defined as the time between the first indicator of diabetes and the date of data extraction (January 1, 2016). Body mass index (BMI) and blood pressure were defined using the value most recently recorded prior to the initiation of the medication of interest. The presence of diabetes complication and comorbidities was determined by the presence of diagnosis codes or other codes specific for the diagnosis (e.g. read code "6A9.." "Atrial fibrillation annual review" as a code to identify the presence of atrial fibrillation). The diabetes complications identified comprised amputation, peripheral neuropathy, retinopathy, and peripheral vascular disease. The comorbidities identified comprised hypertension, atrial fibrillation, angina, stroke, myocardial infarction, congestive cardiac failure, transient ischaemic attack (a history of), coronary artery disease, chronic kidney disease (CKD 3--5), renal replacement therapy (dialysis or transplant), dementia, depression, rheumatoid arthritis, and chronic liver disease (any cause). Chronic kidney disease was identified using estimated glomerular filtration rate (eGFR) measurements and diagnosis codes. Counts of previous and concurrent diabetes medications included fixed-dose combination therapies, which were counted as one additional medication.

All variables included were categorical to account for nonlinear relationships with the outcome measure. Model selection was performed by backwards stepwise elimination of nonsignificant variables (*p* \> 0.05) to minimise the Akaike information criterion (AIC). The outcome event was defined as non-persistence (no repeat prescription collected within 90 days of the previous prescription), with hazard ratios (HR) for non-persistence reported with 95% confidence intervals. Each new medication started was considered a persistence event, so several persistence events were analysed for patients initiated on several medications. We report *R*^2^ as a measure of model performance. We used the statistical package R version 3.3.1 for the statistical analysis.

Compliance with Ethics Guidelines {#Sec4}
---------------------------------

All data used were anonymised at the point of data extraction. No clinically identifiable information was available to researchers. The study was been tested against the Health Research Authority (HRA)/Medical Research Council (MRC) "is this research" tool (<http://www.hra-decisiontools.org.uk/research/>), and was considered to be an audit of current practice when compared to the best available evidence. The study therefore did not require specific ethical approval. Approval for this work was granted by the RCGP RSC study approval committee prior to initiation.

Results {#Sec5}
=======

From a total RCGP RSC cohort of 1,238,909 people from 128 primary care practices, 64,909 (5.2%) people were identified as having diabetes. Of these 60,327 (92.9%) were categorised as type 2 diabetes; a crude prevalence of 6.05% type 2 diabetes in adults. The age-gender direct standardised prevalence for type 2 diabetes in the cohort was 6.25% (95% CI 6.20--6.30%), comparable to the 2011 UK census. In the type 2 diabetes population, the mean age was 66.1 (SD 13.8) years, and 26,792 (41.3%) were female (Table [1](#Tab1){ref-type="table"}).Table 1The characteristics of all adults with identified type 2 diabetes included for analysis (*n* = 60,327)Characteristic*n* (%) or mean (SD)Characteristic*n* (%) or mean (SD)Age recorded60,327 (100.0)HbA1c measured57,159 (94.7)Age (years)66.1 (13.8)HbA1c (mmol/mol)^b^61.9 (22.4)Gender recorded60,327 (100.0)BMI measured59,043 (97.9)Female26,792 (44.4)BMI (kg m^−2^)30.7 (6.4)Ethnicity recorded51,747 (85.8)Blood pressure measured60,106 White42,284 (70.1)SBP (mmHg)132.0 (14.7) Asian5706 (9.5)DBP (mmHg)75.0 (9.6) Black2648 (4.4)Amputation488 (0.8) Mixed552 (0.9)Peripheral neuropathy3845 (6.4) Other557 (0.9)Retinopathy21,408 (35.5)IMD recorded59,830 (99.2)Peripheral vascular disease2191 (3.6) IMD score^a^21.0 (16.3)Hypertension35,657 (59.1)Smoking status recorded60,067 (99.6)Atrial fibrillation5302 (8.8) Never20,227 (33.5)Angina4970 (8.2) Current7932 (13.1)Stroke2605 (4.3) Ex-smoker31,908 (52.9)Myocardial infarction2886 (4.8)Alcohol use recorded54,768 (90.8)Congestive cardiac failure3427 (5.7) None18,469 (30.6)Transient ischaemic attack1960 (3.2) Within limits12,489 (20.7)Coronary artery disease^c^5374 (8.9) Excess23,810 (39.5)Chronic kidney disease^d^11,164 (18.5)Duration of diabetes recorded60,327 (100.0)Renal replacement therapy335 (0.6) \< 4 years18,864 (31.3)Dementia2218 (3.7) 4 ≤ *x* \< 7 years12,066 (20.0)Depression7366 (12.2) 7 ≤ *x* \< 10 years10,994 (18.2)Rheumatoid arthritis1074 (1.8) ≥ 10 years18,403 (30.5)Chronic liver disease3231 (5.4)*SD* standard deviation, *IMD* index of multiple deprivation, *BMI* body mass index, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *LDL* low-density lipoprotein, *eGFR* estimated glomerular filtration rate^a^A higher score equates to a higher level or deprivation, although the scale is nonlinear^b^HbA1c value at the time of diagnosis^c^A composite of myocardial infarction, revascularisation procedures, and acute cardiac syndrome^d^Chronic kidney disease includes stages 3--5 only

The median duration of follow-up was 6.6 (IQR 3.17--10.9) years. During the follow-up period, the majority 42,810 (70.9%) of the people had one or more oral medications prescribed. Metformin was the most commonly prescribed medication, followed by sulfonylureas (Table [2](#Tab2){ref-type="table"}).Table 2The number of people with type 2 diabetes (*n* = 60,327) who were prescribed medication during the follow-up periodMedication classNumber of people prescribed medication in class, *n* (%)Number of medication persistence events, *n*Metformin41,317 (68.5)30,156Sulfonylureas20,819 (34.5)11,347DPP-4 inhibitors9614 (15.9)8125Thiazolidinediones6084 (10.1)4308SGLT2 inhibitors1642 (2.7)1439Meglitinides602 (1.0)244Alpha-glucosidase inhibitors370 (0.6)109The number of medication persistence events can include several medications within the same class taken by a single person where two new prescriptions were identified during the follow-up period

We measured persistence with 55,728 oral medications (Table [2](#Tab2){ref-type="table"}). Non-persistence occurred with 38,169 (68.5%) of those during follow-up. The remaining 17,559 medications had ongoing persistence at the end of follow-up. The median persistence duration overall was 2.25 (95% CI 2.20--2.30) years. Metformin had the longest crude persistence and alpha-glucosidase inhibitors had the shortest, with persistence trends consistent from 6 months to 5 years (Table [3](#Tab3){ref-type="table"}).Table 3Median medication persistence duration and the number of people remaining persistent with medication at 6 months, 1 year, 2 years, and 5 years by medication classMedication classMedian persistence\
years (95% CI)Persistence at 6 months\
% (95% CI)Persistence at 1 year\
% (95% CI)Persistence at 2 years\
% (95% CI)Persistence at 5 years\
% (95% CI)Metformin3.04 (2.94--3.12)80.5 (80.9--80.0)70.1 (70.6--69.6)58.0 (58.6--57.4)39.6 (40.2--39.0)Sulfonylureas2.12 (2.03--2.23)76.6 (77.4--75.8)64.8 (65.7--63.9)51.3 (52.3--50.3)31.6 (32.7--30.6)DPP-4 inhibitors1.69 (1.62--1.78)76.1 (77.0--75.1)62.2 (63.3--61.0)45.5 (46.8--44.2)23.0 (24.5--21.5)Thiazolidinediones1.55 (1.48--1.64)75.6 (76.8--74.2)61.2 (62.7--59.8)43.0 (44.5--41.5)15.7 (16.8--14.5)SGLT2 inhibitorsNA79.5 (81.7--76.9)69.5 (72.5--66.2)54.8 (60.8--48.2)NAMeglitinides0.81 (0.58--1.08)58.4 (64.3--51.8)45.1 (51.3--38.7)28.8 (34.7--23.0)7.5 (11.9--4.3)Alpha-glucosidase inhibitors0.64 (0.27--0.85)52.0 (61.0--42.0)35.3 (44.6--26.2)26.3 (35.4--18.0)13.7 (22.2--7.2)

In Cox regression analyses (Table [4](#Tab4){ref-type="table"}), factors associated with improved medication persistence were found to include older age, male gender, white ethnicity (Fig. [1](#Fig1){ref-type="fig"}), HbA1c 42--60 mmol/mol, presence of hypertension, and no previous glucose-lowering medication use. Factors associated with non-persistence include the presence of neuropathy, a history of myocardial infarction, heart failure, dementia, depression, and chronic liver disease. All medication classes had higher adjusted hazard ratios for non-persistence than for metformin, except for the SGLT2 inhibitors. Variables not associated with persistence (and therefore removed from the model) were smoking status, body mass index (BMI), previous amputations, retinopathy, atrial fibrillation, angina, previous stroke or transient ischaemic attack (TIA), and use of renal replacement therapy.Table 4Results of Cox regression analysis for the hazard ratio (HR) of non-persistence with medication, adjusting for patient characteristics and medication classCharacteristic*n* (%)\*HR (95% CI)*p* valueAge ≤ 30 years373 (0.7)1.66 (1.46--1.87)\< 0.001 30--50 years8912 (16.0)1.00 \[reference\] 51--60 years13,571 (24.4)0.83 (0.80--0.86)\< 0.001 61--75 years23,375 (41.9)0.76 (0.73--0.78)\< 0.001 \> 75 years9497 (17.0)0.75 (0.71--0.78)\< 0.001Male32,162 (57.7)0.93 (0.91--0.95)\< 0.001Ethnicity White40,540 (72.7)1.00 \[reference\] Asian4871 (8.7)1.53 (1.47--1.59)\< 0.001 Black2016 (3.6)1.83 (1.73--1.93)\< 0.001 Mixed453 (0.8)1.29 (1.15--1.45)\< 0.001 Other470 (0.8)1.58 (1.41--1.77)\< 0.001 Not recorded7378 (13.2)0.99 (0.96--1.02)0.598IMD quintile 1 (most deprived)11,228 (20.1)1.00 \[reference\] 29669 (17.4)1.05 (1.02--1.09)0.004 39315 (16.7)1.01 (0.97--1.05)0.614 412,111 (21.7)0.97 (0.94--1.01)0.123 5 (least deprived)13,041 (23.4)0.93 (0.90--0.96)\< 0.001 Not recorded364 (0.7)1.06 (0.92--1.21)0.429Alcohol intake None17,697 (31.8)1.00 \[reference\] Within recommended limits11,327 (20.3)1.02 (0.99--1.05)0.232 Over recommended limits21,849 (39.2)1.00 (0.97--1.03)0.958 Alcoholic1642 (2.9)1.09 (1.02--1.16)0.016 Not recorded3213 (5.8)1.13 (1.07--1.18)\< 0.001HbA1c (mmol/mol) *x* \< 421070 (1.9)1.13 (1.04--1.22)0.004 42 ≤ *x* \< 505139 (9.2)1.00 \[reference\] 50 ≤ *x* \< 6013,428 (24.1)0.95 (0.92--1.00)0.030 60 ≤ *x* \< 7013,922 (25.0)0.99 (0.95--1.03)0.696 70 ≤ *x* \< 10015,902 (28.5)1.10 (1.06--1.15)\< 0.001 ≥ 1004103 (7.4)1.16 (1.10--1.23)\< 0.001 Not measured2164 (3.9)1.16 (1.09--1.24)\< 0.001Duration of diabetes (years) 1--324,922 (44.7)1.00 \[reference\] 4--613,063 (23.4)0.98 (0.95--1.01)0.166 7--910,309 (18.5)0.96 (0.93--0.99)0.013 ≥ 107434 (13.3)0.95 (0.91--0.99)0.012Complications Peripheral neuropathy4604 (8.3)1.08 (1.04--1.12)\< 0.001Comorbidities Hypertension34,060 (61.1)0.96 (0.93--0.98)\< 0.001 Myocardial infarction2678 (4.8)1.07 (1.02--1.12)0.011 Congestive cardiac failure3254 (5.8)1.08 (1.03--1.13)0.002 CKD stages 3--510,647 (19.1)1.09 (1.06--1.12)\< 0.001 Dementia1599 (2.9)1.07 (1.01--1.14)0.027 Depression7286 (13.1)1.08 (1.05--1.12)\< 0.001 Chronic liver disease3492 (6.3)1.12 (1.07--1.17)\< 0.001Number of previous oral glucose-lowering medications None39,986 (71.8)1.00 \[reference\] One10,156 (18.2)1.06 (1.03--1.10)\< 0.001 Two3731 (6.7)1.13 (1.08--1.18)\< 0.001 Three or more1855 (3.3)1.13 (1.06--1.21)\< 0.001Number of concurrent oral glucose-lowering medications None13,164 (23.6)1.00 \[reference\] One20,686 (37.1)1.08 (1.04--1.12)\< 0.001 Two or more21,878 (39.3)0.93 (0.90--0.97)\< 0.001Medication class Metformin30,156 (54.1)1.00 \[reference\] Sulfonylureas11,347 (20.4)1.20 (1.16--1.24)\< 0.001 Thiazolidinediones4308 (7.7)1.71 (1.64--1.77)\< 0.001 DPP-4 inhibitors109 (0.2)1.43 (1.38--1.49)\< 0.001 SGLT2 inhibitors1439 (2.6)1.04 (0.93--1.17)0.458 Meglitinides244 (0.4)2.25 (1.97--2.58)\< 0.001 Alpha-glucosidase inhibitors8125 (14.6)2.45 (1.98--3.02)\< 0.001\**n* and percentage values reflect the number of prescriptions within the study cohort not the number of individualsNumber of medications included = 55,728. Model *R*^2^ = 0.061 Fig. 1A Kaplan--Meier plot of medication persistence in people by ethnicity group. Red line white, blue Asian, yellow black. 95% confidence intervals are shown by the shaded areas

Discussion {#Sec6}
==========

Medication persistence with glucose-lowering agents differs considerably between classes; persistence with metformin was significantly longer than that with any other medication class except for SGLT2 inhibitors (although only a short duration of follow-up was available for this new drug class). Only metformin, sulfonylureas, and SGLT2 inhibitors had more than 50% persistence at 2 years. Alpha-glucosidase inhibitors have the highest rates of non-persistence in clinical practice. Younger people and people of non-white ethnicity had the lowest medication persistence.

The effect size for influence on medication persistence was largest for medication class. This suggests that the class of medication used is the major factor which influences the duration of a selected treatment in type 2 diabetes. Whilst this finding may be unsurprising, it has important implications. Careful selection of second-line therapy after metformin, with a preference for therapies which have longer treatment persistence, may facilitate better long-term diabetes control. However, medication persistence is not uniformly positive. For instance, extended duration of sulphonylureas may not be beneficial as the effects of treatment wane over time when compared to those of an insulin-independent therapy \[[@CR42], [@CR43]\]. Similarly, reduced persistence in those with HbA1c less than 42 mmol/mol suggests appropriate discontinuation in those at risk of hypoglycaemia.

Comparison with the Literature {#Sec7}
------------------------------

We concurred with previous analyses that demonstrated reduced medication adherence in women \[[@CR6], [@CR30], [@CR44], [@CR45]\]. We found that a correlation with reduced duration of mediation persistence remained after adjusting for other factors.

The identified differences in medication persistence between people of different ethnicities should be cause for concern. It has previously been reported that ethnic minorities show reduced medication adherence \[[@CR44], [@CR46], [@CR47]\], but no previous study has been able to adjust for socioeconomic status. The finding that these differences are still substantial in a healthcare system free at the point of delivery, and after adjusting for socioeconomic status, is an important finding. This is particularly so, given that a number of the ethnic groups with shorter medication persistences have higher prevalences of diabetes and diabetes-related complications \[[@CR48]\]. These observed differences merit further investigation. In particular, possible causes of this disparity should be identified.

Our finding concurred with previous studies which found that the presence of depression and other comorbidities was associated with reduced medication adherence \[[@CR49]--[@CR52]\]. However, we found that hypertension was associated with slightly longer persistence. Our findings also concurred with others which have demonstrated reduced adherence in younger people with type 2 diabetes \[[@CR6], [@CR30], [@CR44], [@CR45], [@CR53]\]. We have extended these previous analyses to demonstrate that the association with persistence is non-linear; there is substantially reduced medication persistence in those under 30 years old when compared to the other age groups. This may represent lifestyle factors or be due to early beta-cell failure and a misdiagnosed autoimmune aetiology (with a need for early escalation of therapy) to type 2 diabetes \[[@CR54]\]. These factors which influence medication persistence merit further investigation, and to this end we have initiated a follow-on qualitative analysis of factors influencing medication use in people with type 2 diabetes \[Integrated Research Application System (IRAS) application number; 230092\].

No direct comparison of medication persistence across all groups of diabetes medications has previously been performed \[[@CR55]\]. Our data suggest that medication class is the major influencing factor in medication persistence.

Strengths and Limitations {#Sec8}
-------------------------

The large population size, long duration of follow-up and completeness of the patient record are the main strengths of this analysis. In particular, the availability of a recognised measure of socioeconomic status and of previous and concurrent medication numbers add validity to the conclusion that medication class is the major influencing factor in medication persistence.

Non-persistence is defined retrospectively, with a non-persistence event only identified 90 days after the last medication prescription. This may have artificially inflated the apparent persistence for medications that have not been available for a long time period, such as the SGLT2 inhibitors. Re-evaluation of persistence rates with these medications is needed as more data become available. Our inclusion of drug switching within a class as a non-persistence event may mean our data shows lower persistence rates than others that have not included this. In the absence of a formal definition, we have chosen this method to fit best with previous recommendations \[[@CR34]\].

We were unable to adjust for some factors which have been shown to be associated with medication adherence or persistence, such as proximity to pharmacy, continuity of care, and level of trust in the healthcare provider \[[@CR56]--[@CR58]\]. However, it is unlikely that the inclusion of these factors would substantially alter the associations identified here. Factors underlying the reasons for differences in non-persistence between classes were not explored in this analysis.

Conclusions {#Sec9}
===========

Important factors associated with reduced medication persistence are female gender, younger age, and non-white ethnicity. After adjusting for these and other factors, medication persistence varies considerably across different medication classes and within medication classes, with medication class being the most important predictor of persistence. Metformin was associated with significantly longer persistence than all other medication classes except for SGLT2 inhibitors. SGLT2 inhibitors also show early promise for good persistence, although median persistence was not reached by the end of the follow-up in this study because only a short follow-up duration for this class was available.
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